[Thioredoxin reductase--a new target for molecular medical investigations].
Thioredoxin reductase (TrxR) is the first selenoenzyme containing selenocysteine in the active center and FAD as a second prosthetic group. TrxR catalyses the NADPH-dependent reduction of thioredoxin and of many other physiologically important substrates. TrxR exhibits a many-fold increase in the activity in tumor cells and stimulates their proliferation as well the phenotype changes. Some gold compounds and a number of other clinically and experimentally tested drugs have been shown to inhibit TrxR. The involvement of TrxR/Trx/NADPH system in a broad spectrum of cellular processes renders it a potential target for therapeutic approaches.
Zagrodzki
Paweł
P
Zakład Bromatologii Collegium Medicum Uniwersytetu Jagiellońskiego, Instytut Fizyki Jadrowej im. H. Niewodniczańskiego, Krakowie. zagrodzk@alf.ifj.edu.pl
D000818:Animals; D006801:Humans; D009369:Neoplasms / Q000201:enzymology; D012643:Selenium / Q000172:deficiency / Q000378:metabolism; D013880:Thioredoxin-Disulfide Reductase / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism*
D013880:Thioredoxin-Disulfide Reductase; D012643:Selenium